Clinical Observation of Adenosine Cyclophosphate Combined with Diltiazem in the Treatment of Chronic Pul-monary Heart Disease Heart Failure Complicated with Rapid Atrial Fibrillation and Atrial Flutter / 中国药房

ABSTRACT

OBJECTIVE:To observe clinical efficacy and safety of adenosine cyclophosphate combined with diltiazem in the treatment of chronic pulmonary heart disease heart failure complicated with atrial fibrillation and atrial flutter. METHODS:100 cas-es of chronic pulmonary heart disease heart failure complicated with rapid atrial fibrillation and atrial flutter were randomly divided into observation group and control group,with 50 cases in each group. The control group was given conventional treatment,and the observation group was additionally given diltiazem orally,30 mg/time,once a day,and adenosine cyclophosphate 180 mg add-ed into 5% Glucose injection 200 ml intravenously,once a day,for 10 days,on the basis of conventional treatment. The heart rate,the pressure of pulmonary artery and left ventricular ejection fraction(LVEF)before and after treatment,and clinical efficacy were observed in two groups. RESULTS:After treatment,clinical symptoms of 43 cases of observation group and 31 cases of con-trol group improved significantly,and heart rate were satisfactory,with statistical significance(P<0.05). The decrease of pulmo-nary arterial pressure and LVEF in observation group were improved significantly,compared to control group,with statistical signif-icance (P<0.05). The bradycardia,hypotension,the exacerbation of asthma and heart failure and other side effects hadn’t been found in 2 groups. CONCLUSIONS:Adenosine cyclophosphate combined with diltiazem in the treatment of chronic pulmonary heart disease heart failure complicated with atrial fibrillation and atrial flutter can significantly improve cardiac function,control heart rate and promote the improvement of disease condition with good safety.